Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Voyager Therapeutics

Biogen Idec building

Biogen and Alcyone Therapeutics partner in deal worth over $50m

The companies hope to improve treatments for spinal muscular atrophy and amyotrophic lateral sclerosis

- PMLiVE

Novartis receives EC approval for Pluvicto to treat adult cancer patients

Patients receiving Pluvicto plus best standard of care had a 38% reduction in the risk of death

- PMLiVE

Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study

Around 82.3% of patients achieved haemoglobin-level increases of 2g/dL or more from baseline

- PMLiVE

Novartis partners with Cancer Research UK for rare cancer trial

The trial enrolled both paediatric and adult patients with any rare form of cancer

- PMLiVE

Novartis announces positive phase 3 results for prostate cancer drug Pluvicto

The study met its primary endpoint of radiographic progression-free survival

- PMLiVE

Novartis and MMV to advance new malaria drug combination to phase 3 study

The announcement comes as the threat of resistance to current malaria treatments grows

- PMLiVE

Roche enters into second collaboration with Jnana to address complex drug targets

The Boston-based biotech will receive an upfront payment of $50m

- PMLiVE

Novartis’ Cosentyx receives MHRA approval for two types of juvenile idiopathic arthritis

A phase 3 trial showed significantly longer time to flare for both JPsA and ERA patients

- PMLiVE

Novartis’ Leqvio shows sustained efficacy and safety for cardiac patients

Low-density lipoprotein cholesterol level reduction was sustained over four years

- PMLiVE

Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study

One to two people per million are diagnosed with paroxysmal nocturnal haemoglobinuria each year

- PMLiVE

Novartis bags CHMP recommendation for prostate cancer drug Pluvicto

The recommendation is for use in combination with androgen deprivation therapy

- PMLiVE

Genentech shares positive two-year data for Evrysdi in spinal muscular atrophy study

The study enrolled the ‘broadest and most diverse’ patient population ever studied in an SMA trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links